Daiwa has given WUXI XDC a Buy rating and a target price of HKD78, citing its position as a global leader in the antibody-drug conjugate (ADC) contract research, development, and manufacturing sector. The company is expected to benefit from the growing ADC outsourcing market and its comprehensive service capabilities, leading to significant revenue growth and increased market share in the coming years.
